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Bacteria causing chronic infections predominately grow as surface-attached, sessile communities known as biofilms. Biofilm-related infections including cystic fibrosis lung infection, chronic and recurrent otitis media, chronic wounds and implant- and catheter-associated infections, are a significant cause of morbidity and mortality at great financial cost. Chronic biofilm-based infections are recalcitrant to conventional antibiotic therapy and are often unperturbed by host immune responses such as phagocytosis, despite a sustained presence of  host inflammation. 




















The concept that bacteria exist as single, free-floating (“planktonic”) organisms in nature was radically overturned in the 1970s upon the observation that bacteria were capable of attaching to and growing on a surface, and that these adherent bacteria predominate numerically in natural, clinical and industrial aquatic ecosystems (1). It is now widely accepted that biofilms represent a mode of bacterial growth, allowing survival in hostile environments and colonisation of new niches through dispersal (2). Biofilms are associated with a self-produced hydrated matrix of extracellular polymeric substances (EPS) ADDIN EN.CITE (3, 4), comprising polysaccharides, proteins, lipids and extracellular DNA (eDNA)(5). This matrix confers structure and protection to the complex biofilm community against changing environmental conditions. 

Biofilms – the clinical importance and burden on public health

Bacteria in biofilms can specifically mediate infections which differ from those caused by planktonic bacteria (6). Aside from surface association, aggregation, and the production of a matrix, there are two main differences between biofilm-associated microorganisms and their planktonic counterparts. Biofilms are inherently more tolerant to antibiotics and other forms of antimicrobial treatment, and to host immune responses, despite a sustained presence of inflammatory cells and effector functions  ADDIN EN.CITE (7-9). Clinically, this can result in chronic or recurrent infections such as chronic and recurrent otitis media (COM)(10), chronic wounds (11), cystic fibrosis lung infection (12) and chronic rhinosinusitis (13) (Table 1). 

Biofilm contamination occurs in a range of indwelling medical devices leading to hospital-acquired infections (Table 1). The US Centre of Disease Control (CDC) estimates that biofilms are responsible for more than 65% of such nosocomial infections (14). Currently, the most effective means of treating these infections, and often the only feasible solution, is to physically remove the infected medical device. 


Why do bacteria form biofilms? 









b) Interactive communities and quorum sensing

Bacteria in biofilms are often described as living in a community comparable to those of multicellular organisms. Individual bacteria cells in biofilms are capable of sensing environmental conditions and, through cell-to-cell communication, undergoing changes in their gene expression to increase survival. However, such phenotypic change after adaption of gene expression is only transient and, depending on the conditions, biofilm bacteria may convert back to planktonic growth. Nevertheless, the communal existence and closely packed environment within a biofilm is ideal for intercellular interactions between cells of either the same or different species, benefitting other members of the community and the biofilm as a whole.











When free-floating, planktonic bacteria initially attach to a surface they are not irreversibly bound and are susceptible to antibiotic treatment, gentle rinsing, or changes in conditions.





A profound change in phenotypic expression occurs on the switch from the planktonic to the biofilm growth mode. Microarray studies demonstrate that numerous species variably express as much as ten percent of their genomes in established biofilms compared to planktonic growth conditions  ADDIN EN.CITE (18-21). In some cases, biofilms from different strains of the same bacterial species may be as different from one another as they are from planktonic bacteria (22). 

c) The extracellular matrix

After microcolony formation, an extracellular matrix is produced. Consisting of polysaccharides, proteins and eDNA, the matrix confers physical protection and defines a biofilm by providing the basis for the structure (23). Bacteria also produce increasing amounts of EPS as biofilms become more mature (24). The matrix is crucial in allowing biofilm bacteria to withstand adverse conditions such as high osmotic stress, low nutrient and oxygen availability, antibiotics and host immune responses.


d) Three dimensional structure

A biofilm is not a homogenous monolayer, but synonymous with significant spatial and temporal heterogeneity (25). In addition, the architecture and composition varies according to the bacterial species and the surrounding environment, for instance P.aeruginosa often forms mushroom-shaped microcolonies whereas Streptococcus pneumoniae forms tower-like structures. These structures are interspersed with water channels that enable fluid to penetrate, facilitating efficient exchange of nutrients and oxygen as well as the removal of potentially toxic metabolites (26). This structured consortium of bacteria may also include host proteins such as immunoglobulins, fibrin and platelets.

Biofilm bacteria do not preferentially consume nutrients for growth but rather to make the exopolysaccharide material of the scaffold matrix. However, when nutrients are scarce, the scaffold can be digested by secreted enzymes and used for consumption (27). 


e) Detachment and dispersal

The life cycle of bacterial biofilms ends with the liberation of planktonic bacteria or the detachment of small segments from the mature biofilm that can propagate to other sites. Detachment and dispersal may occur through one of three different mechanisms, which vary according to the bacterial species: clumping dispersal, swarming/seeding dispersal and surface dispersal (28).

Clumping dispersal occurs when a collection of cells are shed from a biofilm as clumps or emboli.  For example, in Staphylococcus aureus biofilms, clumps are continually shed (29) and remain surrounded by the EPS, more closely resembling the attached biofilm than planktonic cells, and exhibiting similar antibiotic resistance. The ability of these non-directed emboli to reattach to a surface may account for the tendency of S.aureus to induce metastasis (30). 

Swarming dispersal occurs when many individual bacteria cells from microcolonies are released into either the bulk fluid or the substratum through the degradative activity of endogenous enzymes  ADDIN EN.CITE (31, 32). Unlike clumping dispersal, bacteria that detach via swarming dispersal are motile, self-propelled and directional, and no longer protected against the host environment (2). Swarming dispersal may be important clinically in cystic fibrosis or bronchiectasis, where infective exacerbations are due to dispersal of bacteria from chronic pseudomonal or multispecies biofilms (33).


Additional Biofilm Characteristics 

a) Oxygen and nutrient gradients





Clinical biofilms are increasingly recognised as being made up of more than one bacterial species. Although not a characteristic of all clinical biofilms, multispecies consortia potentially benefit from interspecies exchange of metabolic substrates and products that allows two or more distinctly different organisms to co-operate with one another in close proximity (known as synthrophism) ADDIN EN.CITE (34, 35). 


Biofilms and antibiotic tolerance

Bacteria in biofilms are highly recalcitrant to conventional antimicrobial treatment  ADDIN EN.CITE (36, 37). Biofilms have been reported to tolerate antimicrobial agents at concentrations 10-1000 times that which are required to eradicate genetically equivalent planktonic bacteria (7). Such resistance is multifactorial, and may be intrinsic (inherent) and/or acquired due to an exchange of genetic information.

Firstly, the self-produced matrix biofilm protects bacteria by retarding the diffusion and penetration of antimicrobials. The matrix of P.aeruginosa biofilms decreases the tobramycin concentration reaching the bacteria by binding to the antibiotic (38), whilst -lactamases at a concerted concentration degrade routinely used beta-lactam based antibiotics (39). Similarly, multidrug resistant (MDR) pumps may contribute to biofilm resistance against low antibiotic concentrations, by transporting antimicrobial molecules out of the cell (40).

Secondly, metabolically inactive cells within biofilms are rendered insusceptible to antimicrobial attack  ADDIN EN.CITE (41, 42), since growth or metabolic activity is a prerequisite for most antibiotic action. In addition, “persister” cells are deeply buried cells insensitive to killing by antibiotics, which can persevere until antibiotic treatment ceases (43).

Importantly, the persister phenotype is not due to nutrient constraints; nor are persisters mutants since their progeny, which are indistinguishable from the original strain, display similar susceptibility to antibiotics as those in the parent biofilm. Instead, persisters appear to be a pre-programmed response to the biofilm mode of growth, a survival mechanism to forego replication in favour of ensuring that some cells will survive such an environmental stress, to subsequently repopulate the biofilm (44).


Detecting and diagnosing biofilm infections 

Diagnosis of biofilm-associated infection (BAI) is a challenge since biofilm bacteria may not be cultured from infected tissues. For example, in otitis media with effusion (OME), a pathogen was identified in 25-30% of cases using culture compared to more than 90% in acute otitis media (AOM) (45). However, pathogens can be detected using polymerase chain reaction (PCR) and with 16S ribosomal probes.

Because conventional culture techniques may fail to detect bacteria in biofilms molecular methods may be helpful in detecting and identifying bacteria when there is a high clinical suspicion of infection. Diagnostic approaches include PCR, fluorescence in situ hybridisation (FISH) in tandem with confocal laser scanner microscopy (CLSM), and more recent novel technologies such as PLEX-ID (46). In OME, pathogens were identified in 80-100% of cases investigated using PCR and/or FISH  ADDIN EN.CITE (10, 45).

Criteria for characterising biofilm-associated infections





a) Current strategies 

Conventional approaches used to treat acute infections may not clear chronic biofilm infections and in many cases promotes resistance and further biofilm formation. Some advocate administration of conventional antibiotics at high doses for prolonged periods of time (49), though no large randomised controlled trials have been carried out. Most current treatment regimens target acute exacerbations caused by planktonic release of bacteria from biofilms, without overall cure.

Currently, the most efficient means of eradicating a clinically significant biofilm remains the surgical removal of the infected implant, or debridement of wound or bone. Such treatment is not always feasible, nor without risk of complications. Clinically significant biofilms remain a challenge to treat.

b) Future directions 

A number of novel approaches for the treatment of clinical biofilm infections are under investigation, such as targeting the QS systems or metabolic pathway manipulation. 

QS inhibitors (QSI) may be an effective future therapeutic option. QS-deficient P.aeruginosa biofilms demonstrated enhanced susceptibility to the synergistic effects of a QSI and tobramycin in vitro and in a mouse model  ADDIN EN.CITE (50, 51). Mice treated with a QSI and tobramycin prophylactically or early post-infection demonstrated substantially reduced colony forming units and increased P.aeruginosa clearance, where prevention of QS-controlled eDNA release and rhamnoliplid production inhibited subsequent antibiotic activity neutralisation and lysis of polymorphonuclear leukocytes, which otherwise promotes biofilm survival (51). 





Bacterial biofilms are a significant cause of morbidity and mortality, and are a major economic burden on global health systems. Novel methods have emerged to diagnose and treat clinical biofilm infections alongside surgical removal and conventional antibiotic therapy. Because antibiotic treatment may be ineffective in eradicating chronic biofilm-related infections, new therapeutic approaches are needed.
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Table 1:- Biofilm-associated infections (48) Chronic Otitis mediaRecurrent tonsillitisChronic woundsCystic fibrosis lung infectionUrinary tract infectionsChronic rhinosinusitis Dental cariesPeriodontitis Device-related infections	Urinary catheters	Mechanical heart valves	Prosthetic joints	Contact lenses            Intrauterine devices            Pacemakers            Endotracheal tubes            Voice prostheses                    Tympanostomy tubes         
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